Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma A Systematic Review and Network Meta-analysis

被引:90
作者
Chang, Ching-Yuan [1 ,2 ]
Park, Haesuk [1 ,2 ]
Malone, Daniel C. [3 ]
Wang, Ching-Yu [1 ,2 ]
Wilson, Debbie L. [1 ]
Yeh, Yu-Min [4 ]
Van Boemmel-Wegmann, Sascha [1 ,2 ]
Lo-Ciganic, Wei-Hsuan [1 ,2 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut Outcomes & Policy, 1225 Ctr Dr,POB 100496,HPNP Bldg,Room 3338, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Pharm, Ctr Drug Evaluat & Safety, Gainesville, FL USA
[3] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA
[4] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
关键词
METASTATIC MELANOMA; COMBINED NIVOLUMAB; IPILIMUMAB; RISK; PEMBROLIZUMAB; CHEMOTHERAPY; MULTICENTER; SURVIVAL; THERAPY;
D O I
10.1001/jamanetworkopen.2020.1611
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Question Does the risk of immune-related adverse events differ across immune checkpoint inhibitors used by patients with advanced melanoma? Findings In this systematic review and network meta-analysis of randomized clinical trials of advanced melanoma treatment, the risk of immune-related adverse events varied by the immune checkpoint inhibitors used and by the different doses of these same immune checkpoint inhibitors. Pembrolizumab, 2 mg/kg, every 3 weeks and 10 mg/kg every 3 weeks as well as nivolumab, 3 mg/kg, every 2 weeks were the 3 immune checkpoint inhibitor regimens associated with the lowest risk of any or severe immune-related adverse events. Meaning Results of this study suggest that network analysis comparing different treatment regimens for advanced melanoma may be valuable for clinical decision-making in the absence of evidence from randomized clinical trials with head-to-head comparisons. This systematic review and meta-analysis evaluates the immune checkpoint inhibitor regimens used along with the incidence of adverse events reported in randomized clinical trials for treatment of advanced melanoma. Importance Since 2011, immune checkpoint inhibitors (ICIs) have been effective treatment options for advanced melanoma. Little is known about how risks of immune-related adverse events (irAEs) vary by ICIs. Objective To compare the risk of irAEs across different treatment regimens for advanced melanoma using network meta-analysis. Data Sources PubMed/MEDLINE, Embase, Web of Science, and Scopus were searched for all randomized clinical trial (RCT) articles published from January 1, 2010, through June 30, 2019. Study Selection Studies included phases 2 and 3 RCTs in the treatment of advanced melanoma that compared ICIs (ipilimumab, nivolumab, and pembrolizumab) with chemotherapy drugs (eg, dacarbazine, carboplatin, and paclitaxel) or different ICI regimens. Data Extraction and Synthesis Different treatment regimens were compared using bayesian network meta-analysis with Markov chain Monte Carlo simulation with noninformative prior distribution and random-effects generalized linear models. Main Outcomes and Measures Primary outcomes were the cumulative incidence of any irAEs (regardless of severity) and severe irAEs (grades 3-5). Based on the pooled odds ratios (ORs) and 95% credible intervals (95% CrI), the probability of being associated with the lowest irAE risks was estimated for each treatment regimen. Results Nine RCTs with 8 different treatment regimens for advanced melanoma and involving a total of 5051 patients were included. Overall, the 3 ICI treatment regimens associated with the lowest risk of any or severe irAEs were pembrolizumab, 2 mg/kg, every 3 weeks; nivolumab, 3 mg/kg, every 2 weeks; and pembrolizumab, 10 mg/kg, every 3 weeks. Compared with ipilimumab, 10 mg/kg, every 3 weeks, only nivolumab, 3 mg/kg, every 2 weeks, was associated with a decreased risk for any irAEs (OR, 0.34; 95% CrI, 0.13-0.94). A decreased risk for severe irAEs was observed for ipilimumab, 3 mg/kg, every 3 weeks (OR, 0.35; 95% CrI, 0.14-0.74); pembrolizumab, 10 mg/kg, every 2 weeks (OR, 0.22; 95% CrI, 0.05-0.95) and 10 mg/kg every 3 weeks (OR, 0.20; 95% CrI, 0.06-0.68); and nivolumab, 3 mg/kg, every 2 weeks (OR, 0.20; 95% CrI, 0.07-0.48) compared with ipilimumab, 10 mg/kg, every 3 weeks. An increased risk for severe irAEs was associated with nivolumab, 1 mg/kg, every 3 weeks combined with ipilimumab, 3 mg/kg, every 3 weeks compared with other ICI regimens (ORs ranging from 4.09 [95% CrI, 1.73-10.99] to 7.40 [95% CrI, 1.12-49.29]) except ipilimumab, 10 mg/kg, every 3 weeks. Conclusions and Relevance These findings suggest that for patients with advanced melanoma at high risk of irAEs, pembrolizumab, 2 mg/kg, every 3 weeks, nivolumab, 3 mg/kg, every 2 weeks, and pembrolizumab, 10 mg/kg, every 3 weeks may be the preferred treatment regimens (with respect to irAE risks) among the ICI regimens reported, whereas ipilimumab, 10 mg/kg, every 3 weeks alone and nivolumab, 1 mg/kg, every 3 weeks combined with ipilimumab, 3 mg/kg, every 3 weeks should be used with caution. A network analysis may be valuable for clinical decision-making when evidence from head-to-head comparisons is lacking.
引用
收藏
页数:13
相关论文
共 36 条
[1]   Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
Fouad, Mona .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (03) :183-193
[2]   Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
FUTURE ONCOLOGY, 2016, 12 (03) :413-425
[3]   Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
IMMUNOTHERAPY, 2015, 7 (11) :1213-1227
[4]   Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
EXPERT OPINION ON DRUG SAFETY, 2015, 14 (10) :1507-1518
[5]   Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis [J].
Abdel-Rahman, Omar ;
ElHalawani, Hesham ;
Fouad, Mona .
FUTURE ONCOLOGY, 2015, 11 (17) :2471-2484
[6]   Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].
Ascierto, Paolo A. ;
Del Vecchio, Michele ;
Robert, Caroline ;
Mackiewicz, Andrzej ;
Chiarion-Sileni, Vanna ;
Arance, Ana ;
Lebbe, Celeste ;
Bastholt, Lars ;
Hamid, Omid ;
Rutkowski, Piotr ;
McNeil, Catriona ;
Garbe, Claus ;
Loquai, Carmen ;
Dreno, Brigitte ;
Thomas, Luc ;
Grob, Jean-Jacques ;
Liszkay, Gabriella ;
Nyakas, Marta ;
Gutzmer, Ralf ;
Pikiel, Joanna ;
Grange, Florent ;
Hoeller, Christoph ;
Ferraresi, Virginia ;
Smylie, Michael ;
Schadendorf, Dirk ;
Mortier, Laurent ;
Svane, Inge Marie ;
Hennicken, Delphine ;
Qureshi, Anila ;
Maio, Michele .
LANCET ONCOLOGY, 2017, 18 (05) :611-622
[7]   Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].
Brahmer, Julie R. ;
Lacchetti, Christina ;
Schneider, Bryan J. ;
Atkins, Michael B. ;
Brassil, Kelly J. ;
Caterino, Jeffrey M. ;
Chau, Ian ;
Ernstoff, Marc S. ;
Gardner, Jennifer M. ;
Ginex, Pamela ;
Hallmeyer, Sigrun ;
Chakrabarty, Jennifer Holter ;
Leighl, Natasha B. ;
Mammen, Jennifer S. ;
McDermott, David F. ;
Naing, Aung ;
Nastoupil, Loretta J. ;
Phillips, Tanyanika ;
Porter, Laura D. ;
Puzanov, Igor ;
Reichner, Cristina A. ;
Santomasso, Bianca D. ;
Seigel, Carole ;
Spira, Alexander ;
Suarez-Almazor, Maria E. ;
Wang, Yinghong ;
Weber, Jeffrey S. ;
Wolchok, Jedd D. ;
Thompson, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+
[8]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330
[9]   Checking consistency in mixed treatment comparison meta-analysis [J].
Dias, S. ;
Welton, N. J. ;
Caldwell, D. M. ;
Ades, A. E. .
STATISTICS IN MEDICINE, 2010, 29 (7-8) :932-944
[10]   Circulating Tumor Cells in Stage IV Melanoma Patients [J].
Hall, Carolyn S. ;
Ross, Merrick ;
Bauldry, Jessica B. Bowman ;
Upshaw, Joshua ;
Karhade, Mandar G. ;
Royal, Richard ;
Patel, Sapna ;
Lucci, Anthony .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (01) :116-124